



209 High Point Drive, #100
Victor, NY 14564

T 585 385-6810
coopervision.com

CooperVision Myopia Control Research Receives Second Garland W. Clay Award

Second Recognition in Four Years Highlights the Significance of MiSight® 1 day Clinical Trial Findings

Richmond Hill, ON, October 1st, 2025—CooperVision’s research and development team, led by Senior Director of Research Programs Paul Chamberlain, along with their coauthors, has once again received the prestigious Garland W. Clay Award, presented annually by the American Academy of Optometry. This marks the second time in four years that CooperVision’s pioneering work in myopia control has received the honor, underscoring the company’s enduring leadership and impact in advancing eye health worldwide.

The 2025 award recognizes the paper, *“Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial”* (Chamberlain P. et al.), published in Optometry and Vision Science (OVS). The award honors the authors of the most significant paper in OVS over the past five years: Paul Chamberlain, Arthur Bradley, Baskar Arumugam, David Hammond and John McNally, CooperVision; Nicola S. Logan, Aston University, United Kingdom; Deborah Jones, University of Waterloo, Canada; Cheryl Ngo, National University Hospital, Singapore; Sofia C. Peixoto-De-Matos, University of Minho, Portugal; Chris Hunt and Graeme Young, Visioncare Research, United Kingdom.

“I am incredibly honored, along with my coauthors, to receive the Garland W. Clay Award for a second time in such a short period,” said Chamberlain. “We are passionate about sharing the MiSight® 1 day study findings with the global eye care professional community, presenting research that is balanced, clinically meaningful, and practical, which are all values Garland Clay championed. This recognition also belongs to the investigators, staff, children and their families whose long-term commitment was essential to every insight we’ve shared.”

This six-year publication, the second installment in the trilogy of landmark MiSight® 1 day clinical trial papers, demonstrated the sustained treatment effect of the lens in slowing myopia progression,

reinforcing its clinical value.* It follows the three-year results paper, which earned the [2021 Garland W. Clay Award](#), and precedes the publication of the findings of the final year of the seven-year study, completing the longest continuous international investigation of its kind for myopia control soft contact lenses among children. Collectively, the trilogy provides unmatched evidence of MiSight® 1 day's safety and effectiveness in slowing the progression of myopia in children.

“To be recognized with the Garland W. Clay Award for a second time is an extraordinary testament to the quality, impact, and enduring relevance of our research,” said Jennifer Lambert, Vice President, Myopia Management & Cornea Care, CooperVision. “This three-part study not only shaped the global scientific conversation around myopia management but also translated into real-world benefits for children and families worldwide.”

The American Academy of Optometry will formally present the 2025 Garland W. Clay Award to the authors on Friday, October 10, during its annual meeting in Boston. The publication is available online via [Open Access](#).

#

* While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a

workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Media Contact

Mary Doyle

Blend PR for CooperVision Canada

mary@blendpr.com or (416) 907-0977